ACP puts hormone therapy first for menopause symptoms
Estrogen-based therapy is now recommended first for vasomotor symptoms, with SNRIs, SSRIs, gabapentin, and neurokinin receptor antagonists reserved for later lines.
By
Teraya Smith
October 6, 2026
Clinical Scorecard: ACP puts hormone therapy first for menopause symptoms
At a Glance
Category Detail
Condition Menopausal vasomotor symptoms Key Mechanisms Estrogen therapy reduces symptom severity and frequency, improves quality of life. Target Population Perimenopausal and postmenopausal patients Care Setting Clinical guideline for hormone therapy management
Key Highlights
Estrogen combined with progestogen is recommended for patients with a uterus. Estrogen monotherapy is recommended for patients without a uterus. Desvenlafaxine or venlafaxine are recommended as second-line treatments. Gabapentin and neurokinin receptor antagonists are third-line options. The lowest effective dose of estrogen is advised. Guideline-Based Recommendations
Diagnosis
Clinicians should inquire directly about vasomotor symptoms. Management
First-line treatment is estrogen therapy; second-line includes certain antidepressants. Monitoring & Follow-up
Assess treatment efficacy after 8 to 12 weeks. Risks
Increased risks of stroke, venous thromboembolism, and breast cancer associated with estrogen therapy. Patient & Prescribing Data
Generally healthy postmenopausal patients aged 49 to 57 years.
Evidence in perimenopausal patients is limited; most studies excluded patients with significant comorbidities.
Clinical Best Practices
Avoid initiating hormone therapy after age 60 or more than 10 years post-menopause. Limit treatment duration to 3 to 5 years, though optimal duration is unknown. Related Resources & Content
